Lycopene Blood Pressure Meta-analysis: What the Evidence Says

Quick Answer

Lycopene Blood Pressure Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Major risk factors such as dyslipidemia, hypertension, diabetes, smoking, obesity, and genetic predisposition accelerate this cascade, highlighting the multifactorial nature of atherogenesis. [Cavero-Redondo Iván (2026); evidence level 1]
• The assessment of atherosclerosis has improved significantly, with carotid intima-media thickness (IMT) being among the most widely used and validated noninvasive markers. [Cavero-Redondo Iván (2026); evidence level 1]
• Among these, lycopene, a naturally occurring carotenoid predominantly found in tomatoes and other red fruits, has been extensively studied for its strong antioxidant activity and possible protective role against chronic diseases. [Sikorska-Zimny Kalina (2026); evidence level 4]
• Extensive meta-analyses have shown that lycopene and tomato product supplementation significantly reduce cardiovascular risk factors, particularly by lowering low-density lipoprotein (LDL) cholesterol. [Sikorska-Zimny Kalina (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For lycopene blood pressure meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Cavero-Redondo Iván (2026). Circulating Lycopene and β-Carotene Levels Are Inversely Associated with Carotid Intima–Media Thickness: A Systematic Review and Meta-Analysis. DOI: 10.3390/nu18071043. PMCID: PMC13074833. PMID: 41978094. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13074833/
• Sikorska-Zimny Kalina (2026). Preliminary Quality and Safety Evaluation of Lycopene-Based Dietary Supplements: Analysis of Active Compound Content, Microbiological Purity, and Chemical Contaminants. DOI: 10.3390/foods15091583. PMCID: PMC13164322. PMID: 42121526. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13164322/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.